Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 5NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 19Other hematologic neoplasm 18Myeloid 5Head & Neck 4Plasma cell 3Dermatologic 3Thoracic 2Gastrointestinal 2Classical hematology 2Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Advanced Solid Tumor 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × fludarabine phosphate × Other solid neoplasm × Clear all
NCT06241456 2025-12-09

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Recruiting
351 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡